×
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
Sattar N., Preiss D., Robinson JG., Djedjos CS., Elliott M., Somaratne R., Wasserman SM., Raal FJ.
DOI
10.1016/S2213-8587(16)00003-6
Type
Journal article
Journal
The Lancet Diabetes & Endocrinology
Publication Date
02/2016